The latest news about Montara

Montara Therapeutics, a biotechnology company pioneering brain-selective therapies for CNS diseases, today announced the appointment of Andrew Miller, Ph.D., to its Board of Directors; the hiring of David Michelson, M.D., as Chief Medical Officer; and the promotion of Zachary Hill, Ph.D., to Chief Technology Officer.

Building on a prior MJFF-funded collaboration targeting LRRK2, Montara’s BrainOnly™ platform now targets the mTOR pathway — exploring a class of drugs with longstanding scientific interest but a history of safety challenges.

Montara’s BrainOnly platform is designed to prevent peripheral side effects and concentrate neurological drugs’ activity in the brain via two-drug combination therapies, comprising its non−brain-penetrant “universal” peripheral blocker development candidate, MT1110, and a brain-penetrant target-specific drug. Montara will enter the clinic in H2 2026 to study an MT1110-everolimus combination, called MTX-E1, for the treatment of TSC-related epilepsy and other mTOR-driven CNS diseases.

Montara Therapeutics awarded $3.3 million non-dilutive MJFF grant to develop BrainOnly™ Parkinson’s therapy targeting LRRK2, a genetically validated target with major drug development challenges. New collaboration to use Montara’s BrainOnly platform to create a next-generation brain-selective LRRK2 inhibitor that avoids the irreversible toxicity from unselective peripheral activity.